EGFR exon 19 deletion

Clinical trials for EGFR exon 19 deletion explained in plain language.

Never miss a new study

Get alerted when new EGFR exon 19 deletion trials appear

Sign up with your email to follow new studies for EGFR exon 19 deletion, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Can a smart drug outperform chemo for Hard-to-Treat lung cancer?

Disease control Ongoing

This phase 3 trial compares an experimental drug called patritumab deruxtecan with standard platinum-based chemotherapy in people with a specific type of non-small cell lung cancer that has an EGFR mutation and has progressed after EGFR-targeted therapy. The drug is designed to d…

Matched conditions: EGFR EXON 19 DELETION

Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control

Last updated Aug 29, 2026 00:00 UTC

EGFR exon 19 deletion

Get alerted when new EGFR exon 19 deletion trials appear

Can a smart drug outperform chemo for Hard-to-Treat lung cancer?